枸橼酸他莫昔芬片的制备及质量评价

目的 探索枸橼酸他莫昔芬片的处方和制备工艺,并对其进行质量评价。方法 通过考察填充剂比例、黏合剂浓度、崩解剂用量、润滑剂用量、颗粒大小和水分含量等,筛选最优处方比例及制备工艺。制备若干批枸橼酸他莫昔芬片（1 000片/批）,对颗粒休止角、药物晶型、片质量差异、硬度、崩解时限、含量等进行质量评价;同时,建立多条溶出曲线利用相似因子法评价自制片与参比制剂的相似性。结果 选用本处方和工艺条件制备的枸橼酸他莫昔芬片质量符合中国药典2015年版中的相关质量要求;4种溶出介质中溶出曲线的相似因子f₂值均>50。结论 枸橼酸他莫昔芬自制片与参比制剂具有体外溶出一致性。     

Multiple tamping effects on drug dissolution from capsules filled on a dosing-disk type automatic capsule filling machine

The effects of number of tamps and tamping force on drug dissolution from capsules filled on an instrumented dosing-disk automatic capsule filling machine (Hofliger-Karg) were studied using hydrochlorothiazide as a model, low dose, poorly soluble drug. Generally, there was a trend toward slower dissolution rate with increasing numbers of tamps, the effect being most marked when insoluble dicalcium phosphate dihydrate was the filler. Higher compression forces improved drug release when anhydrous lactose was the filler, but adversely affected the dicalcium phosphate-based capsules. Inclusion of 4% croscarmellose sodium disintegrant tended to nullify the effects of number of tamps or tamping force with both fillers; however, the disintegrant also markedly enhanced drug dissolution from the dicalcium phosphate-based formulation. Hydrochlorothiazide dissolution from the latter formulation without disintegrant appeared to follow a "diffusion from insoluble matrix" model regardless of number of tamps or their intensity. Mercury intrusion pore size distribution data for some plugs suggested that for tamps of equal force (100 or 200 N), further powder consolidation after two tamps does not occur.     

Influence of water uptake,gel network,and disintegration time on prednisone release from encapsulated solid dispersions

Prednisone is considered the glucocorticoid of choice for anti-inflammatory and immunosuppressant effects. However, its very low aqueous solubility can compromise oral bioavailability. Changes in the dissolution of a prednisone-PEG 6000 solid dispersion into capsule were investigated by addition of pregelatinized starch. Physical state of prednisone:PEG 6000 was analyzed by X-ray diffractometry, and scanning electron microscopy. Capsule formulations containing prednisone-PEG 6000 and pregelatinized starch showed superior dissolution properties (>?95% in 60?min) when compared with reference capsules without disintegrant (<?45% in 60?min). Water uptake and disintegration time were directly correlated with pregelatinized starch amount. The morphology of prednisone-PEG 6000 particles with disintegrant was analyzed by SEM, showing a novel surface structure. Thus, solid dispersions of a poorly water soluble drug combined with a disintegrant were confirmed as a valid approach to the improvement of drug dissolution.     

Evaluation of the Functional Equivalence of Crospovidone NF from Different Sources. II. Standard Performance Test

Current NF monographs do not provide tests that reflect on the functionality of Crospovidone NF from multiple sources. Physical characterization studies such as particle size and distribution, surface area, porosity, and surface morphology revealed major differences among the crospovidones from different sources (Shah, U.; Augsburger, L.L. J. Pharm. Dev. Technol. 2001, 6 (1), 39–51). Differences in disintegration and dissolution were also observed for a model drug in an insoluble filler system (see Shah and Augsburger, 2001). The objective of this study was to determine the relationship between physical differences observed and disintegrant functionality and to develop standard performance test. Tests performed included settling volume studies, measurement of initial rate as well as extent of liquid uptake of the loose disintegrant powder, and simultaneous measurement of the axial and radial disintegrating forces along with the rate and extent of liquid uptake of the pure disintegrant compacts. Significant differences among the crospovidones were observed for all tests performed. Settling volume, liquid uptake, and disintegration force are recommended as standard performance tests to determine differences among crospovidones from different sources.     

In vitro pharmaceutical characterization and statistical optimization of a novel topically applied instantly-soluble solid eye drop matrix

Abstract

Ocular diseases of the anterior segment of the eye are increasing and the development of novel drug delivery systems for improved treatment is necessary. The aim of this study was therefore to design and evaluate an instantly-soluble solid eye drop (ISED) for topical ophthalmic drug delivery of the model drug timolol maleate. The porous nature of the lyophilized ISED resulted in rapid fluid ingression, immediate hydration, and dissolution of the ocular matrix. The ISED was lyophilized employing hydroxypropylcellulose and pluronic® F68 as the matrix forming polymers. Polyacrylic acid sodium enhanced the solubility of the ISED, di-glycine, an anti-collapsing agent, while maltodextrin improved the matrix resilience. A statistical design was employed for optimizing the texture, disintegration, and the mean dissolution time (MDT_50%) of the ISED. Results revealed that a robust rapidly disintegrating ISED was produced with the fastest disintegration time recorded at 0.20?s and drug release between 79 and 96%. In addition, improved corneal drug permeation was observed compared to pure timolol dispersion. The maltodextrin concentration significantly affected the ISED matrix resilience (p?=?0.007) and pluronic F68 had a greater impact on disintegration time (p?=?0.000) and MDT (p?=?0.000). The ISED formulation may be a promising alternative to the use of liquid eye drops for topical ophthalmic drug delivery.     

Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: Development,optimization and in vitro/in vivo studies

A liquisolid orodispersible tablet of felodipine, a BCS Class II drug, was developed to improve drug dissolution and absorption through the buccal mucosa for management of hypertensive crisis. A 24 full-factorial design was applied to optimize felodipine liquisolid systems (FLSs) having acceptable flow properties and possessing enhanced drug dissolution rates. Four formulation variables; The liquid type, X1 (PG or PEG), drug concentration, X2 (10% and 20%), type of coat, X3 (Aerosil® and Aeroperl®) and excipients ratio, X4 (10 and 20) were included in the design. The systems were assessed for dissolution and flow properties. Following optimization, the formulation components (X1, X2, X3 and X4) were PEG, 10%, Aerosil® and 20, respectively. The optimized FLS was compressed into felodipine liquisolid orodispersible tablet using Prosolv® as carrier material (FLODT-2). The in vitro and in vivo disintegration times of FLODT-2 were 9 and 7 s, respectively. The in vivo pharmacokinetic study using human volunteers showed a significant increase in dissolution and absorption rates of the formulation of FLODT-2 compared to soft gelatin capsules filled with felodipine solution in PEG under the same conditions. Our results proposed that the optimized FLODT formulation could be promising to manage hypertensive crisis.     

An easy-to-use approach for determining the disintegration ability of disintegrants by analysis of available surface area

With the aim of directly predicting the functionality and mechanism of disintegrants during the disintegration and dissolution of tablets, we investigated an analysis method based on available surface area, which is the surface area of a drug in a formulation in direct contact with the external solvent during dissolution. We evaluated the following disintegrants in this study: sodium starch glycolate (Glycolys), crospovidone (Kollidon CL), carboxymethylcellulose calcium (CMC-Ca), low-substituted hydroxypropylcellulose (L-HPC), and croscarmellose sodium (Ac-Di-Sol). When disintegrant was added to a 50% ethenzamide tablet formulation, an increase in the dissolution rate dependent on disintegrant concentration was observed, according to the type of disintegrant. In addition, the available surface area also differed between disintegrants. For Glycolys, CMC-Ca, and Ac-Di-Sol, a rapid increase in available surface area and a large increase in maximum available surface area (S_max) were observed due to high swellability and wicking, even when the disintegrant concentration was only 1.0%. In contrast, for Kollidon CL and LH-21, a gradual increase in available surface area was observed, depending on the disintegrant concentration. To evaluate the disintegrant ability, Δt_max and ΔS_max were calculated by subtracting peak time (t_max) at 5.0% from that at 1.0% and subtracting S_max at 1.0% from that at 5.0%, respectively, and it was found that the water absorption ratio had strong negative correlations with Δt_max and ΔS_max. Therefore, this study demonstrates that analysis of only available surface area and parameters thereby obtained can directly provide useful information, especially about the disintegration ability of disintegrants.     

Drug-excipient interactions resulting from powder mixing. III: Solid state properties and their effect on drug dissolution

Micronized prednisone was used to study the effect of powder mixing on drug-excipient interactions and their effect on in vitro dissolution from uncompacted, hand-filled capsules. Two powder formulations contained CaHPO4 X 2H2O (dibasic calcium phosphate dihydrate) as a filler and potato starch or sodium starch glycolate as a disintegrant. The third powder formulation contained pregelatinized starch as a disintegrant/filler. The lubricant in these formulations was magnesium stearate. When drug, CaHPO4 X 2H2O, and the disintegrant were thoroughly mixed and hand filled into capsules without compaction, only approximately 70% of the drug dissolved in 30 min. The incomplete dissolution of the drug was caused by the formation of agglomerates and the inclusion of the drug particles by these agglomerates. In contrast, when a mixture of drug and pregelatinized starch was used, complete dissolution of the drug was achieved after 30 min due to the absence of agglomeration and inclusion. Prolonged mixing of the formulation containing CaHPO4 X 2H2O with magnesium stearate resulted in a decrease in the dissolution rate. The total amount of the drug dissolved at the end of 30 min was reduced from 70 to 20%. The decrease in the rate of drug dissolution resulted from drug-excipient interactions which caused flaking of the magnesium stearate particles. The adhesion of these flakes to the drug particles and drug-excipient agglomerates resulted in hydrophobic coating which reduced water penetration. The rate of drug dissolution was not affected when drug and pregelatinized starch were mixed with magnesium stearate for a prolonged time due to the absence of magnesium stearate flaking and film formation.     

盐酸决奈达隆片的处方优化及溶出度评价研究

目的：筛选盐酸决奈达隆片的处方组成,并评价其溶出度。方法以盐酸决奈达隆的溶出度为指标,采用L9(34)正交试验优化盐酸决奈达隆片处方主要因素填充剂乳糖–淀粉比例、黏合剂聚维酮 K30的乙醇体积分数、增溶剂波洛沙姆用量、崩解剂交联聚维酮用量。以赛诺菲–安万特公司原研制剂迈达龙为参比制剂,采用 f2相似因子法进行盐酸决奈达隆溶出曲线的相似度评价。结果盐酸决奈达隆片的最佳处方为填充剂比例2∶1,选用5%PVP K3040%乙醇溶液为黏合剂,泊洛沙姆188用量为2%,交联聚维酮用量为3%。在不同pH值的溶出介质中,自制制剂和参比制剂的溶出曲线f2相似因子均大于50。结论自制制剂与参比制剂在不同pH值的溶出介质中得体外溶出行为相似。     

Effect of the mode of incorporation on the disintegrant properties of acid modified water and white yam starches

Acid modified starches obtained from two species of yam tubers namely white yam – Dioscorea rotundata L. and water yam – D. alata L. DIAL2 have been investigated as intra- and extra-granular disintegrants in paracetamol tablet formulations. The native starches were modified by acid hydrolysis and employed as disintegrant at concentrations of 5 and 10% w/w and their disintegrant properties compared with those of corn starch BP. The tensile strength and drug release properties of the tablets, assessed using the disintegration and dissolution (t₅₀ and t₈₀ – time required for 50% and 80% of paracetamol to be released) times, were evaluated. The results showed that the tensile strength and the disintegration and dissolution times of the tablets decreased with increase in the concentration of the starch disintegrants. The acid modified yam starches showed better disintegrant efficiency than corn starch in the tablet formulations. Acid modification appeared to improve the disintegrant efficiency of the yam starches. Furthermore, tablets containing starches incorporated extragranularly showed faster disintegration but lower tensile strength than those containing starches incorporated intragranularly. This emphasizes the importance of the mode of incorporation of starch disintegrant.     

Search for technological reasons to develop a capsule or a tablet formulation with respect to wettability and dissolution

Proquazone, a poorly wettable compound, was used as a model drug in the search for reasons to develop a capsule or tablet formulation. The capsules were filled with proquazone as active ingredient, with lactose monohydrate (200 mesh) as filler and with magnesium stearate as lubricant. The tablet was made out of a granulate as internal phase which consisted of proquazone as active ingredient, lactose as filler, corn starch as disintegrant and PVP as a binding agent. The external phase consisted of magnesium stearate and corn starch. The concentration of proquazone in the capsule and in the tablet formulation was varied. The capsule formulations showed a significantly slower dissolution of the drug substance than the tablet formulations especially for a high-drug load. Independently of the drug load, only the tablet formulation showed a high-dissolution rate. Thus, concerning drug load, only the tablet formulations showed to be robust. It became clear that proquazone needs to be formulated as a granulate or a tablet to achieve a fast dissolution rate. Thus, a poorly wettable drug, especially when it is found in high concentrations, can have direct impact on the decision to develop a tablet or a capsule formulation.     

New oral solid dosage form for furosemide oral administration

Furosemide (FURO) is a drug labeled in class IV of the Biopharmaceutics Classification System (BCS) as it is both poor soluble and poor permeable. The aim of this work was to improve FURO biopharmaceutical properties by its formulation in a new solid oral dosage form. It consists in the realization of the composite MgAl-HTlc-FURO, obtained by FURO intercalation into the inorganic matrix hydrotalcite (MgAl-HTlc), and its successive formulation in tablets intended to be swallowed whole and to disintegrate rapidly in the stomach. These formulations were prepared by direct compression of a simple powder mixture constituted by MgAl-HTlc-FURO, a super disintegrant (Explotab, PolyplasdoneXL, PolyplasdoneXL-10, PolyplasdoneINF 10 or L-HPCLH-21) and a filler. The prepared formulations were submitted to disintegration time tests, and only those displaying the lowest disintegration time in gastric medium were submitted to in vitro release studies. Drug dissolution profiles from MgAl-HTlc-FURO tablets were compared with those containing crystalline FURO alone or physically mixed to MgAl-HTlc instead of MgAl-HTlc-FURO. The results revealed that tablets containing MgAl-HTlc-FURO give the best dissolution profile and that L-HPCLH-21 is able to promote the highest drug release in gastric medium, resulting in the most suitable super disintegrant in comparison with the other tested.     

Design of freeze-dried Soluplus/polyvinyl alcohol-based film for the oral delivery of an insoluble drug for the pediatric use

Abstract

Spironolactone (SL) is a poorly water-soluble drug. Being poorly soluble affects its dissolution rate which in turn affects its oral bioavailability. This work aimed to prepare freeze-dried SL-Soluplus®/polyvinyl alcohol (PVA) oral thin film in an attempt to enhance the drug solubility on one hand and at the same time prepare a solid dosage form convenient for the pediatric use. SL-Soluplus®/PVA films were prepared using polyethylene glycol 400 (PEG 400) as a plasticizer applying the solvent-casting technique. The prepared films were evaluated for their thickness, tensile strength, and in vitro dissolution studies. Box–Behnken design (17 runs) was applied to optimize the effects of the formulation variables on the film properties. The optimized film formulation was freeze-dried after casting so as to enhance the drug dissolution. Moreover, the optimized freeze-dried film was re-characterized in vitro and evaluated in vivo in human volunteers to investigate its palatability and satisfaction. The results showed that the optimized formulation composed of 10% polymer concentration containing Soluplus®:PVA (0.33:0.66) and plasticized with 30% PEG 400 possessed the highest desirability value (0.836). Freeze-drying of the optimized formulation succeeded to improve SL in vitro dissolution due to the preparation of a more porous film compared to the non-freeze-dried one. In vivo evaluation of the optimized freeze-dried film showed high satisfaction among the participating volunteers concerning the ease of administration and sensation thereafter, where all the film specimens dissolved without the need for water and no film residues remained in the mouth following film dissolution. In conclusion, freeze-dried Soluplus®/PVA-based oral thin film proved to be a successful carrier for the oral delivery of insoluble drugs like SL for pediatrics.     

Development and optimization of formulation for treatment of copper deficiency in human organism

The aim of this study was to design and optimize a new tablet formulation for treatment of copper deficiency in human organism by using an experimental design. The new no-veneered tablets, prepared by a wet granulation technique, are containg active substance, a copper(II) complex with polysaccharide pullulan. The binder concentration, the disintegrant concentration and the resistance to crushing were used as independent variables in the formulation, while in vitro measured drug release characteristics of the tablets was response variable in a full factorial design 2(3) modeling. A cubic model for data fitted was used to examine the obtained results. They showed that the resistance to crushing has the most significant effect on copper(II) complex release from the formulation, while the disintegrant concentration has smaller influence on dissolution profile of copper(II) complex and the binder concentration had minor impact in this study. Lower value of resistance to crushing has influence on better dissolution profile. Furthermore, physical characteristics of the tablets were evaluated, viz., drug content, hardness, thickness, friability, disintegration time, mass variation, particle size and size distribution.     

The Effect of Cross-Linking on the In Vivo Disintegration of Hard Gelatin Capsules

Purpose. To evaluate if the cross-linking of gelatin affects in vivo capsule disintegration. Methods. Scintigraphic investigation in nine healthy volunteers to provide for a real time visualisation of capsule disintegration. Results. The moderately stressed capsules failed the USP dissolution specification for acetaminophen capsule when tested in water and conventional SGF but passed with the addition of pepsin. Moderately stressed capsules started to disintegrate at 10 ± 6 minutes (range 6 to 24 minutes) compared to 8 ± 2 minutes (range 5 to 11 minutes) for the unstressed capsule. Conclusions. The results of the study clearly demonstrate that with the incisive technique of gamma scintigraphy there are no differences in the in vivodisintegration properties of moderately stressed and unstressed capsules.     

Enhancing tablet disintegration characteristics of a highly water-soluble high-drug-loading formulation by granulation process

Abstract

The objective of this study was to improve the disintegration and dissolution characteristics of a highly water-soluble tablet matrix by altering the manufacturing process. A high disintegration time along with high dependence of the disintegration time on tablet hardness was observed for a high drug loading (70% w/w) API when formulated using a high-shear wet granulation (HSWG) process. Keeping the formulation composition mostly constant, a fluid-bed granulation (FBG) process was explored as an alternate granulation method using a 2^(4?1) fractional factorial design with two center points. FBG batches (10 batches) were manufactured using varying disingtegrant amount, spray rate, inlet temperature (T) and atomization air pressure. The resultant final blend particle size was affected significantly by spray rate (p?=?.0009), inlet T (p?=?.0062), atomization air pressure (p?=?.0134) and the interaction effect between inlet T*spray rate (p?=?.0241). The compactibility of the final blend was affected significantly by disintegrant amount (p?<?.0001), atomization air pressure (p?=?.0013) and spray rate (p?=?.05). It was observed that the fluid-bed batches gave significantly lower disintegration times than the HSWG batches, and mercury intrusion porosimetry data revealed that this was caused by the higher internal pore structure of tablets manufactured using the FBG batches.     

Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble grapefruit flavonoid Naringenin: design,characterization, in vitro and in vivo evaluation

Abstract

Naringenin (NRG), predominant flavanone in grapefruits, possesses anti-inflammatory, anti-carcinogenic, hepato-protective and anti-lipid peroxidation effects. Slow dissolution after oral ingestion due to its poor solubility in water, as well as low bioavailability following oral administration, restricts its therapeutic application. The study is an attempt to improve the solubility and bioavailability of NRG by employing self-nanoemulsifying drug delivery technique. Preliminary screening was carried out to select oil, surfactant and co-surfactant, based on solubilization and emulsification efficiency of the components. Pseudo ternary phase diagrams were constructed to identify the area of nanoemulsification. The developed self-nanoemulsifying drug delivery systems (SNEDDS) were evaluated in term of goluble size, globule size distribution, zeta potential, and surface morphology of nanoemulsions so obtained. The TEM analysis proves that nanoemulsion shows a droplet size less than 50?nm. Freeze thaw cycling and centrifugation studies were carried out to confirm the stability of the developed SNEDDS. In vitro drug release from SNEDDS was significantly higher (p?<?0.005) than pure drug. Furthermore, area under the drug concentration time-curve (AUC_0–24) of NRG from SNEDDS formulation revealed a significant increase (p?<?0.005) in NRG absorption compared to NRG alone. The increase in drug release and bioavailability as compared to drug suspension from SNEDDS formulation may be attributed to the nanosized droplets and enhanced solubility of NRG in the SNEDDS.     

Comparative bioavailability of josamycin,a macrolide antibiotic,from a tablet and solution and the influence of dissolution on in vivo release

The bioavailability of josamycin from a tablet formulation (2 × Josacine® 500 mg tablets) was investigated and compared with the bioavailability of a solution (containing 1 g drug and buffered at pH 4.0) following administration to six healthy human volunteers. Bioavailability profiles for the solution indicated that the drug was inherently rapidly absorbed with a mean C_max of 1.64±0.67 mg L⁻¹ attained at a mean t_max of 0.39±0.08 h. The AUC_0–last was 1.510±0.687 mg h L⁻¹. Bioavailability was significantly lower from the tablets than from the solution. Highly variable serum concentration–time profiles were obtained from the tablets and C_max values ranged from 0.05 to 0.71 mg L⁻¹ with a t_max range of 0.33–2.0 h. AUC_0–last values ranged from 0.03 to 0.95 mg h L⁻¹. Dissolution of josamycin from the tablets was generally unaffected at low pH (pH 1.2–5.0), but, rather, limited predominantly by tablet disintegration. However, dissolution was increasingly limited as the pH increased from 5.0 to 9.0. Besides poor disintegration, the particularly low intrinsic dissolution rate and solubility of josamycin at these pH values is likely to further reduce the dissolution rate. Comparison of the solution and tablet serum concentration–time profiles suggests that the absorption of josamycin from the tablets was dissolution rate limited. This is supported by the in vitro dissolution–pH topogram, which suggests that dissolution will be particularly rate limiting if dissolution of whole or parts of tablets occurs in gastro-intestinal fluid above pH 5.0. © 1998 John Wiley & Sons, Ltd.     

缬沙坦胶囊处方工艺筛选及溶出度评价

目的 研制以诺华制药产品“代文”(规格：80 mg)为仿制目标的缬沙坦胶囊。方法 通过比较自制制剂和原研制剂的体外溶出数据,筛选处方和工艺。为了达到两者溶出曲线一致,分析不同厂家原料药对溶出的影响,并对处方内增溶剂用法和用量进行考察。结果 调整处方解决原料药难溶会降低溶出度的问题,采用f2因子法比较仿制胶囊和“代文”在多介质中的溶出曲线,体外两者溶出相似。结论 最终的处方和工艺具有可行性,仿制制剂和原研制剂体外溶出相似性可为体内两者质量一致提供一定依据。     

The influence of polymorphism on the manufacturability and in vitro dissolution of sulindac-containing hard gelatin capsules

Abstract

Context: Drug polymorphism could affect drug product dissolution, manufacturability, stability and bioavailability/bioequivalence. The impact of polymorphism on the manufacturability and in vitro dissolution profiles of sulindac capsules has not been studied yet.

Objective: To evaluate the impact of polymorphism on the manufacturability and in vitro dissolution of sulindac hard gelatin capsules.

Materials and methods: Sulindac crystal forms I and II (SLDI and SLDII, respectively) were prepared and characterized. Powder formulations containing one of the polymorphs, lactose and magnesium stearate (at three different levels) were prepared and their flow properties determined. Hard gelatin capsules were filled with the formulations and tested for fill-weight variations. Drug dissolution for SLDI- and SLDII-containing hard gelatin capsules was determined.

Results: Differences in flow properties for each polymorph were observed, as well as for their formulations, which in turn affected capsule weight homogeneity. Statistically significant differences in the rate and extent of drug release were observed between SLDI- and SLDII-containing capsules.

Discussion: Formulations containing SLDI showed a better manufacturability and a better dissolution profile than those with SLDII.

Conclusion: Sulindac crystalline form I was the best candidate for hard gelatin capsule formulation because of its technological and in vitro dissolution properties.